[Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe].
The efficacy of isepamycin vs. other aminoglycosides was studied in vitro and on albino mice with experimental plague due to natural antigen valuable strains of the plague microbe and the pathogen variants deprived of the ability to produce the capsular antigen fraction I (FI- phenotype). The MICs of isepamycin for the strains of the plague microbe (20 FI+ and 20FI-) were 1.0-4.0 mg\l, that did not differ from those of streptomycin, kanamycin, amikacin and tobramycin. The ED50 of isepamycin in the prophylaxis and treatment of the experimental plague of the mice had no statistically significant differences from the ED50 of the other aminoglycosides. The efficacy index of isepamycin was > 10(4), that did not differ from that of streptomycin, amikacin and gentamicin, irrespective of the strain phenotype (Y. pestis 231 FI+ or Y. pestis 231 FI-). The same as the other aminoglycosides, isepamycin in doses equivalent to the human average daily doses, protected 80-100% of the albino mice from death when used in the prophylaxis and therapy of plague irrespective of the strain phenotype. The results of the study made it possible to consider isepamycin as an agent promising for the prophylaxis and treatment of plague.
Smorodinova
Iu V
IuV
Shcherbaniuk
A I
AI
Ryzhko
I V
IV
Moldavan
I A
IA
D000617:Aminoglycosides / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000235:genetics; D005839:Gentamicins / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D009154:Mutation; D010930:Plague / Q000188:drug therapy* / Q000517:prevention & control*; D015010:Yersinia pestis / Q000187:drug effects* / Q000235:genetics
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D005839:Gentamicins; C086725:caf1 protein, Yersinia pestis; C016927:isepamicin